Which GLP-1 is best for your situation?

For women

The best GLP-1 for women: what the trial evidence actually supports

On efficacy alone, tirzepatide (Zepbound) produced the largest mean weight loss in trials for both sexes. But "best for women" is really about matching the drug to your specific situation — PCOS, perimenopause, or a pregnancy plan each change the calculus. There is no female-specific GLP-1.

Read the evidence

For men

The best GLP-1 for men: what the trial evidence actually supports

For men, the decision often hinges on cardiovascular risk. Semaglutide (Wegovy) has the SELECT cardiovascular-outcomes evidence — a 20% MACE reduction in adults with heart disease. If maximum weight loss is the goal and CV risk is not the driver, tirzepatide (Zepbound) led on efficacy.

Read the evidence

For adults over 50

The best GLP-1 for adults over 50: what the evidence supports

After 50, the decision weighs cardiovascular benefit and muscle/bone preservation more heavily. Semaglutide (Wegovy) carries the SELECT cardiovascular evidence; tirzepatide leads on weight loss. The bigger determinant of a good outcome after 50 is aggressive lean-mass protection, not the drug choice itself.

Read the evidence

For women with PCOS

Ozempic for PCOS: what the evidence actually supports

For PCOS, both semaglutide and tirzepatide target the underlying insulin resistance and can restore ovulation. Tirzepatide produces larger weight loss and may drive greater metabolic improvement, but the most important point is not which drug — it is that returning fertility requires reliable contraception unless you are planning pregnancy.

Read the evidence

For people with insulin resistance or prediabetes

The best GLP-1 for insulin resistance and prediabetes

For insulin resistance and prediabetes, GLP-1s both drive weight loss and directly improve glycemic control. Tirzepatide (dual GIP/GLP-1) produced the largest HbA1c and weight reductions in trials; semaglutide has extensive diabetes-prevention data. Either substantially reduces progression to type 2 diabetes.

Read the evidence

For people with type 2 diabetes

Ozempic vs Mounjaro for type 2 diabetes: which controls blood sugar better?

For raw glycemic control plus weight loss, tirzepatide (Mounjaro) has the strongest data — the SURPASS program showed the largest HbA1c reductions in the class. Semaglutide (Ozempic) is the pick when cardiovascular or kidney outcomes drive the decision, backed by SUSTAIN-6 and the FLOW kidney trial.

Read the evidence

For people with obstructive sleep apnea

Zepbound for sleep apnea: what SURMOUNT-OSA actually showed

For obstructive sleep apnea with obesity, tirzepatide (Zepbound) is the clear evidence-based choice — SURMOUNT-OSA led the FDA to approve it as the first drug for this indication, with apnea events falling roughly 25-30 per hour. Coverage is often easier under the OSA indication than for weight loss alone.

Read the evidence

For people who have had bariatric surgery

The best GLP-1 after bariatric surgery: managing weight regain

Adding a GLP-1 after bariatric surgery is an established, evidence-supported strategy for weight regain or insufficient loss. Tirzepatide has the larger weight effect; semaglutide has the deeper outcomes evidence. The bigger issues post-surgery are nutrient monitoring and tolerability, not which of the two you pick.

Read the evidence

For people with a BMI of 40 or higher

The best GLP-1 for BMI 40+: severe obesity and the surgery question

At BMI 40+, tirzepatide (Zepbound) has the strongest weight-loss evidence and is the usual first choice. But the honest framing is that medication and bariatric surgery are complementary, not competing — surgery still produces larger and more durable loss at this BMI, and the right answer for many is a real conversation about both.

Read the evidence